Geron Corporation (Nasdaq: GERN) today announced that management will present a company overview at two upcoming investor conferences.
  • Rodman & Renshaw Annual Global Investment Conference in New York City. David L. Greenwood, Geron’s President and Chief Executive Officer, will present at 9:35 a.m. EDT on Tuesday, September 13, 2011.
  • UBS Global Life Sciences Conference in New York City. Hoyoung Huh, M.D., Ph.D., Geron’s Executive Chairman, and Stephen M. Kelsey, M.D., Executive Vice President, Head of Research & Development and Chief Medical Officer will present at 10:30 a.m. on Wednesday, September 21, 2011.

The webcasts for the live audio and slide presentations will be available on the “Investors” pages of the company’s website, www.geron.com. The presentations will be archived for replay and available on the Geron website one hour after conclusion of the live event.

About Geron

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases. The company is advancing anti-cancer therapies through multiple Phase 2 clinical trials in different cancers by targeting the enzyme telomerase and with a compound designed to penetrate the blood-brain barrier. The company is developing cell therapies from differentiated human embryonic stem cells for a range of indications, with the first product in a Phase 1 clinical trial for spinal cord injury. For more information, visit www.geron.com.

Copyright Business Wire 2010

If you liked this article you might like

Geron Shares Take a Dive After J&J Unit-Led Trial Falters; Endo Closes Higher: Biotech Movers

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Biotech Premarket Movers: Innoviva, Akebia, Geron

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Geron (GERN) Stock Rises on $80 Million Janssen Licensing Deal